These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19301459)

  • 41. "Lunch and learn" with Dr. Melanie Thompson sheds light on IL2.
    Wilder TL
    Surviv News (Atlanta Ga); 2001 Aug; ():12-3. PubMed ID: 11682743
    [No Abstract]   [Full Text] [Related]  

  • 42. [New groups of drugs for HIV infection therapy].
    Rozsypal H
    Klin Mikrobiol Infekc Lek; 2008 Dec; 14(6):223-4. PubMed ID: 19378497
    [No Abstract]   [Full Text] [Related]  

  • 43. Mortality of HIV-infected patients in low-income countries.
    Kadhiravan T; Sharma SK
    Lancet; 2006 Dec; 368(9554):2207; author reply 2207-8. PubMed ID: 17189025
    [No Abstract]   [Full Text] [Related]  

  • 44. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interleukin-2 as therapy for HIV disease. Dinitrochlorobenzene Study Group.
    Goldberg B
    N Engl J Med; 1995 Jul; 333(3):192; author reply 193. PubMed ID: 7791830
    [No Abstract]   [Full Text] [Related]  

  • 46. Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal.
    De Beaudrap P; Etard JF; Diouf A; Ndiaye I; Guèye NF; Guèye PM; Sow PS; Mboup S; Ndoye I; Ecochard R; Eric D;
    Am J Trop Med Hyg; 2009 Jun; 80(6):1047-53. PubMed ID: 19478274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changing the presumption: providing ART to vaccine research participants.
    Macklin R
    Am J Bioeth; 2006; 6(1):W1-5. PubMed ID: 16423765
    [No Abstract]   [Full Text] [Related]  

  • 48. Public-sector ART in the Free State Province, South Africa: community support as an important determinant of outcome.
    Wouters E; Van Damme W; Van Loon F; van Rensburg D; Meulemans H
    Soc Sci Med; 2009 Oct; 69(8):1177-85. PubMed ID: 19692165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin-2 as therapy for HIV disease.
    Disla E
    N Engl J Med; 1995 Jul; 333(3):192; author reply 193. PubMed ID: 7646690
    [No Abstract]   [Full Text] [Related]  

  • 50. [CD4 lymphocytes as targets and actors in the pathogenesis of HIV infection--therapeutic implications].
    Theze J
    Bull Acad Natl Med; 2008 Oct; 192(7):1453-66; discussion 1466-8. PubMed ID: 19445368
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oscillatory viral dynamics in a delayed HIV pathogenesis model.
    Wang Y; Zhou Y; Wu J; Heffernan J
    Math Biosci; 2009 Jun; 219(2):104-12. PubMed ID: 19327371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New recommendations for the management of HIV].
    Chevillotte J
    Rev Infirm; 2013 Dec; (196):6. PubMed ID: 24427906
    [No Abstract]   [Full Text] [Related]  

  • 54. Inexpensive CD4 counting for the developing world.
    Secko D
    CMAJ; 2005 Aug; 173(5):478. PubMed ID: 16129864
    [No Abstract]   [Full Text] [Related]  

  • 55. Management of the patient with HIV disease.
    Sharma SK; Kadhiravan T
    Dis Mon; 2008 Mar; 54(3):162-95. PubMed ID: 18294976
    [No Abstract]   [Full Text] [Related]  

  • 56. Cell counts in children rebound after treatment.
    AIDS Policy Law; 2015 May; 30(6):1. PubMed ID: 26117850
    [No Abstract]   [Full Text] [Related]  

  • 57. Body image is a major determinant of sexual dysfunction in stable HIV-infected women.
    Luzi K; Guaraldi G; Murri R; De Paola M; Orlando G; Squillace N; Esposito R; Rochira V; Zirilli L; Martinez E
    Antivir Ther; 2009; 14(1):85-92. PubMed ID: 19320240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
    J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A wake-up call for global access to salvage HIV drug regimens.
    Mills EJ; Nachega JB
    Lancet; 2007 Dec; 370(9603):1885-7. PubMed ID: 18068497
    [No Abstract]   [Full Text] [Related]  

  • 60. Prioritizing antiretrovirals for second-line therapy in resource-limited countries.
    Naidoo K
    AIDS Clin Care; 2008 May; 20(5):43. PubMed ID: 19230296
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.